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Abstract 
Background: Advances in mass spectrometry have accelerated biomarker discovery in many areas of medicine. The 
purpose of this study was to compare two mass spectrometry (MS) methods, isobaric tags for relative and absolute 
quantitation (iTRAQ) and sequential window acquisition of all theoretical fragment ion spectra (SWATH), for analytical 
efficiency in biomarker discovery when there are multiple methodological constraints such as limited sample size and 
several time points for each patient to be analyzed.
Methods: A total of 140 tear samples were collected from 28 glaucoma patients at 5 time points in a glaucoma drug 
switch study. Samples were analyzed with iTRAQ and SWATH methods using NanoLC-MSTOF mass spectrometry.
Results: We discovered that even though iTRAQ is faster than SWATH with respect to analysis time per sample, it 
loses in sensitivity, reliability and robustness. While SWATH analysis yielded complete data of 456 proteins in all sam-
ples, with iTRAQ we were able to quantify 477 proteins in total but on average only 125 proteins were quantified in a 
sample. 283 proteins were common in the datasets produced by the two methods. Repeatability of the methods was 
assessed by calculating percent relative standard deviation (% RSD) between replicate MS analyses: SWATH was more 
repeatable (56% of proteins < 20% RSD), compared to iTRAQ (43% of proteins < 20% RSD). Despite the overall benefits 
of SWATH, both methods showed less than 1 log fold change difference in the expression of 74% common proteins. 
In addition, comparison to MS/MS peptide results using 8 isotopically labeled peptide standards, SWATH and iTRAQ 
showed similar results in terms of accuracy. Moreover, both methods detected similar trends in a longitudinal analysis 
of protein expression of two known tear biomarkers.
Conclusions: Overall, we conclude that SWATH should be preferred for biomarker discovery studies when analyzing 
limited volumes of clinical samples collected at multiple time points.
Trial Registeration: The study was approved by the Ethics Committee at Tampere University Hospital and was regis-
tered in EU clinical trials register (EudraCT Number: 2010-021039-14).
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
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Background
Biomarkers can reveal a patient’s risk to certain disease 
or complication and its severity, and predict the thera-
peutic response [1]. In recent years mass spectrometry 
(MS) has become an attractive choice for biomarker 
discovery, because it can be used to detect and quantify 
most proteins in a given sample [2, 3] and it can thus 
detect changes in cellular functions and metabolism in a 
more comprehensive way than the traditional immunoas-
says [4]. In ophthalmology, tissue samples are always very 
limited in amount due to the size of the eye and potential 
damage to healthy structures. However, the tear fluid is a 
thin layer of extra-cellular fluid over the surface of the eye 
[5] that can be collected non-invasively. MS analysis of 
tear samples has proven its potential in discovering pro-
teomic biomarkers and even small quantities of tear flu-
ids are sufficient if collected and analyzed carefully [6–9]. 
Tear fluid proteomics is relevant for understanding the 
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outcomes of topically applied drugs, adverse reactions, 
anterior segment surgery, inflammatory diseases such as 
dry eye as well as other eye and systemic diseases [8–10].
iTRAQ or isobaric tags for relative and absolute quan-
titation [11, 12] has often been the method of choice for 
relative quantitation, but more recently a new technique, 
sequential windowed acquisition of all theoretical frag-
ment ion mass spectra (SWATH) [13], has begun to chal-
lenge that position as an alternative method. SWATH and 
iTRAQ provide relative quantitation using very different 
approaches. Unlike SWATH, iTRAQ sample preparation 
requires preparatory steps to covalently bind isobaric 
labels to peptides which usually represent 4 or 8 different 
experimental groups depending on the study [11–13].
Data dependent acquisition (DDA) method is often 
used in iTRAQ experiment, which has been widely 
used for relative quantitation of proteins in clinical and 
in  vitro studies [14–17]. Usually, the iTRAQ studies 
have been fairly small (< 40 samples), with total protein 
amount > 30 µg/sample [16–19] and in general, 25 µg of 
total protein has been regarded as a limit for successful 
iTRAQ labeling. iTRAQ has not been applied for large 
clinical trials because of the high costs of the reagents, 
complexity of the study setups and propensity of iTRAQ 
to yield incomplete data based on stochastic selection of 
peptides.
SWATH is a data independent acquisition (DIA) 
method where the instrument deterministically frag-
ments all precursor ions within the predefined mass-
to-charge (m/z) range and acquires convoluted product 
ion spectra containing all the fragment ions of all the 
concurrently fragmented precursors [13]. This results 
in a data set that is continuous in both fragment ion 
intensity and retention time dimensions and essentially 
represents a digital recording of all analyzed proteins in 
the sample [3]. In SWATH, datasets are recorded inde-
pendently and can be re-examined if the library used in 
downstream analyses is updated. In addition, SWATH 
is label free and therefore not limited to a specific num-
ber of experimental groups [13]. SWATH was first pre-
sented by Gillet et  al. [13], since then multiple different 
articles on the subject have been published [9, 21, 22]. 
DIA methods are also suitable for analysis of extremely 
small sample amounts [9, 23], which is crucial for small 
and non-reproducible clinical samples, common in many 
clinical specialties such as ophthalmology. SWATH 
allows more flexible comparisons and potential savings, 
especially when sample amount is limited [13].
iTRAQ and SWATH both produce relative quantita-
tion results which need further validation using other 
methods in order to increase the reliability of discovery 
proteomics. Suitable methods for this purpose include 
different immunochemical methods and targeted MS/
MS analysis. However, ELISA assays and Western blot-
ting are both often limited by selectivity and multiplex-
ing possibilities with small samples [24, 25]. Targeted 
MS/MS analysis is currently the only mass spectrometry 
method which can produce absolute quantification of tar-
geted proteins using isotopically labeled peptide stand-
ards (AQUA) or protein standard absolute quantification 
(PSAQ) [26, 27]. Use of isotope standards minimizes the 
sample preparation and mass spectrometry equipment 
variation thus increase the reliability and accuracy of 
results [28].
We compared iTRAQ and SWATH in terms of sensi-
tivity, reliability and robustness in tear fluid samples col-
lected from 28 patients over five time points in a clinical 
drug switch study. In addition, we evaluated similarity of 
relative quantification results to 2 stable isotope labeled 
protein peptides (AQUA) quantification results obtained 
by MicroLC-MS/MS.
Methods
Chemicals and materials
Acetonitrile (ACN), formic acid (FA), water (UHPLC-
MS grade), triethylammonium bicarbonate buffer 1  M 
(TEAB), sodium dodecyl sulfate (SDS), methyl meth-
anethiosulfate (MMTS), trifluoroacetic acid (TFA), 
ammonium bicarbonate (ABC) and urea were all pur-
chased from Sigma Aldrich (St. Louis, MO, USA). Pro-
tease inhibitor cocktail (HALT) and sample cleaning tips 
(C18) were from Thermo Fisher Scientific (San Jose, CA, 
USA). BioRad DC protein quantification kit and serum 
albumin standard were purchased from Bio-Rad (Her-
cules, CA, USA) and 30  kDa filters from PALL (Port 
Washington, NY, USA). 8-plex iTRAQ reagent kit and 
TPCK treated trypsin was acquired from Sciex (SCIEX, 
Framingham, MA, USA).
Sample collection and preparation
The study was approved by the Ethics Committee at Tam-
pere University Hospital and was registered in EU clinical 
trials register (EudraCT Number: 2010-021039-14).
The study outline, sample preparation and analysis are 
schematically presented in Fig.  1. The study was per-
formed on 28 glaucoma patients who had been using 
latanoprost as topical glaucoma medication for the 
minimum of 2  years prior to switching to preservative-
free medication. Patients’ eyes were clinically examined 
by an ophthalmologist and tear samples were collected 
with Schirmer’s strips 0, 1.5, 3, 6 and 12 months after the 
drug change. No topical anesthesia was used in tear sam-
ple collection and gloves were worn by all investigators 
handling the samples. The samples were stored at − 80 °C 
until processed.
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Fig. 1 Illustration of study outline, different analyses completed in the study and sample amounts
Page 4 of 11Jylhä et al. Clin Proteom  (2018) 15:24 
Protein extraction and enzymatic digestion
For extraction of tear proteins, Schirmer’s strips were 
first cut into small pieces and solubilized to 50 mM ABC 
solution containing HALT™ protease inhibitor, incu-
bated on ice for 60  min and centrifuged. Total protein 
concentration of the supernatant was measured with 
Bio-Rad DC protein quantification kit, using serum 
albumin as a standard. For iTRAQ 25 or 50  µg and for 
SWATH 6–50  µg of total protein was precipitated with 
cold acetone (− 20  °C) overnight. The protein amounts 
were selected based on the manufacturer’s recommen-
dation in iTRAQ and our previous testing of suitable 
injection volume of 1.5  µg total protein in 2  µl volume 
in SWATH. Precipitated proteins were centrifuged, liq-
uid layer was decanted from the tubes and samples were 
allowed to dry for 10  min. Proteins were solubilized in 
0.5  M TEAB, denatured with 0.1% SDS and reduced by 
Tris-(2-carboxyethyl) phosphine and set to thermo mixer 
for 60 min of incubation at + 60 °C. After reduction sam-
ples were transferred into Pall  Nanosep® 30 kDa MWCO 
centrifugal devices with low protein binding membrane 
and flushed three times with 200  µl of 75% urea solu-
tion for additional denaturation. Cysteine residues were 
blocked by MMTS at room temperature in dark. Sam-
ples were flushed with additional urea solution twice, and 
urea was removed with 50 mM ABC. Samples were then 
subjected to enzymatic digestion (trypsin:protein ratio 
1:25  µg) for 16  h at + 37  °C. The following day samples 
were flushed with 50 Mm ABC to remove peptides from 
the filter and dried in speed vacuum. SWATH samples 
were solubilized to 0.1% TFA and desalted with C18 fil-
ter tips. Desalting was done by first cleaning the filter by 
aspirating 50% ACN and 0.1% TFA through the tip, then 
sample was aspirated 7 times, followed by cleaning aspi-
ration with 5% ACN. Final elution was done by 80% ACN 
and 0.1% FA. Samples were dried in speed vacuum and 
stored at − 20 °C until used for iTRAQ labeling or recon-
stituted to loading solution (5% ACN, 0.1% FA) before 
NanoRPLC-MSTOF SWATH analysis. SWATH analy-
sis samples were diluted to equal concentrations before 
injection to the instrument.
iTRAQ labeling
Each iTRAQ reagent (113, 114, 115, 116, 117, 118, 119, 
122 isobaric tags) was reconstituted in ethanol, and pep-
tide samples were reconstituted in iTRAQ dissolution 
buffer. Samples were labelled with the iTRAQ reagents 
one patient at a time (5 samples = 5 labels per patient). 
The labelled samples were incubated for 2 h at room tem-
perature with interval mixing (alternating 1  min static 
and 15 min at 1200 rpm), centrifuged at 13,500 rpm for 
5  min, and pooled (Fig.  1). The pooled samples were 
dried by vacuum centrifugation. Sample clean-up and 
desalting was carried out using Macro Spin Column Fil-
ters (Nest Group Inc, Southborough, MA) and washing 
samples several times with ACN and TEAB buffers. The 
samples were dried in vacuum centrifugation and stored 
at − 20 °C until analyzed.
NanoRPLC‑MSTOF
NanoLC-MSTOF parameters used in iTRAQ analysis 
have been published before in [17] and SWATH method 
has been published before [9]. Digested peptides were 
analyzed by Nano-RPLC-MSTOF instrumentation 
using Eksigent 425 NanoLC coupled to high speed Tri-
pleTOF™ 5600 + mass spectrometer (Ab Sciex, Concord, 
Canada). A capillary RP-LC column  (cHiPLC® ChromXP 
C18-CL, 3  µm particle size, 120  Å, 75  µm i.d × 15  cm, 
Eksigent Concord, Canada) was used for LC separation 
of peptides. Samples were first loaded into trap column 
 (cHiPLC® ChromXP C18-CL, 3 µm particle size, 120 Å, 
75  µm i.d × 5  mm) from autosampler and flushed for 
10  min at 2  µl/min (2% ACN, 0.1% FA). The flush sys-
tem was then switched to line with analytical column. 
Tear samples were analyzed with 120 min 6 step gradient 
using eluent A: 0.1% FA in 1% ACN and eluent B: 0.1% FA 
in ACN (eluent B from 5 to 7% over 2 min, 7 to 24% over 
55 min, 24 to 40% over 29 min, 40 to 60% over 6 min, 60 
to 90% over 2 min and kept at 90% for 15 min, 90 to 5% 
over 0.1 min and kept at 5% for 13 min) at 300 nl/min.
Key parameters for TripleTOF mass spectrometer in 
iTRAQ and SWATH ID library analysis were: ion spray 
voltage floating (ISVF) 2300  V, curtain gas (CUR) 30, 
interface heater temperature (IHT) + 125 °C, ion source 
gas 1 13, declustering potential (DP) 100  V. Library for 
SWATH analysis was created from the same samples 
by information dependent-acquisition (IDA) method 
and relative quantitation analysis was done by SWATH 
method. All methods were run by Analyst TF 1.5  soft-
ware (Ab Sciex, USA). For DDA parameters, 0.25  s MS 
survey scan in the mass range 350–1250  m/z were fol-
lowed by 60 MS/MS scans in the mass range of 100–
1500 Da (total cycle time 3.302 s). Switching criteria were 
set to ions greater than mass to charge ratio (m/z) 350 
and smaller than 1250 (m/z) with charge state 2–5 and 
an abundance threshold of more than 120 counts. Former 
target ions were excluded for 12  s. IDA rolling collision 
energy (CE) parameters script was used for automatically 
controlling CE. SWATH quantification analysis param-
eters were the same as for SWATH ID, with the following 
exceptions: cycle time 3.332 s and MS parameters set to 
acquire an MS scan in the range of 350–1250 Da followed 
by 40 MS/MS scans of 15 Da windows spanning the mass 
range 350–1250 Da.
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MicroLC‑MS/MS analysis with AQUA peptides
Sixteen patients were selected for MS/MS analysis. Selec-
tion of patients was based on what samples had suf-
ficient amount tear fluid left for MS/MS analysis after 
iTRAQ and SWATH analyses. We selected 8 proteins 
and one peptide from each for MicroLC-MS/MS analy-
sis (Table 1). Sample preparation was similar to SWATH 
samples and AQUA peptides were added in the final 
elution step before injecting to MS/MS analysis. Con-
centration of AQUA peptide was matched to the mean 
concentrations of each peptide in the tear samples. Cor-
responding isotopically labeled peptides were purchased 
from Sigma-Aldrich (purity > 95%).
Tear samples were analyzed with Sciex 6500 + MSTrap 
which was coupled to NanoLC 425 with 1–10  µl/min 
microLC flow cell. Acclaim™ PepMap™ C18, analytical 
C18, 300 Å, 5 µm, 0.3 × 150 mm HPLC column was pur-
chased from Thermo Fisher scientific. MicroLC utilized 
a 42 min 6 step gradient using eluent A: 0.1% FA in MQ 
and eluent B: 0.1% FA in ACN (eluent B from 10 to 30% 
over 22 min, 30 to 50% over 8 min, 50 to 80% over 2 min, 
kept at 80% for 5 min, 80 to 10% over 0.2 min and kept at 
10% for 5 min, at 5 µl/min. MSTrap settings were as fol-
lows; Curtain gas: 30, Spray voltage: 5300, Collision gas: 
medium, Temperature: 150 °C, Ion source gas 1: 20, Ion 
sourece gas 2: 20, were set the same for all peptides. Col-
lision energy was set to 30 for all fragments and corre-
sponding isotopes.
Data analysis
ProteinPilot software version 4.0.8085 (AB Sciex, Can-
ada) was used for database searching (IPI v. 3.87) for 
building library for SWATH analysis and iTRAQ analy-
sis. Some important settings in the Paragon search algo-
rithm in ProteinPilot were configured as follows. Sample 
type: identification, Cys-alkylation: MMTS, Digestion: 
Trypsin, Instrument: TripleTOF 5600 +, Search effort: 
thorough ID. False discovery rate (FDR) analysis was 
performed in the ProteinPilot and FDR < 1% was set for 
protein identification. Peptide identification limit was 
set to 99%. The data from all the identification runs were 
combined as a batch and used for library creation.
PeakView® software 2.0 with SWATH was used to 
assign the correct peaks to correct peptides in the library. 
iRT peptides (Biognosys, Switzerland) was used for 
retention time calibration with PeakView. 1–15 peptides 
per protein were selected to be used in SWATH quanti-
fication. All shared peptides were excluded from analy-
sis. SWATH plug-in FDR analysis was used to select the 
proper peptides for use in quantification. For all compari-
son data between iTRAQ and SWATH all proteins with 
relative quantitation data based on single peptide were 
removed from results.
All statistical analyses were performed with Excel or 
R statistical software version 3.2.3 (R Core Team. Foun-
dation for Statistical Computing, Vienna, Austria. URL: 
https ://www.R-proje ct.org/). Relative standard deviations 
(% RSD) were calculated from two replicate MS analyses 
in order to assess repeatability of iTRAQ and SWATH. 
Duplicate proteins with identical gene names were 
merged, keeping only the protein name with the high-
est ranking (number of proteins after duplicate check, 
iTRAQ n = 667, SWATH n = 680, Additional file 1).
For MS/MS quantification method we used 3 point 
smoothing in peak integration and all 3 peptide fragment 
chromatograms were combined for each protein. Quanti-
fied peptides areas were normalized against their corre-
sponding isotopically labeled standard peptide peak areas 
to remove instrument variability. Analysis method was 
validated in terms of sample preparation, linearity and 
repeatability.
Results
All of the iTRAQ and SWATH analyses were performed 
using identical TripleTOF 5600 + MS and NanoLC set-
tings. A total of 14 days of instrument time was required 
for iTRAQ analyses and 35  days for SWATH analyses. 
Altogether 140 tear samples were processed, however, 
Table 1 Proteins and their specific peptides and fragments used in MS/MS quantification analysis
Protein Peptide sequence Mass (Da) Corresponding isotope
LYZ STDYGIFQINSR 1400.7 (H)STDYGIFQINS(RC13N15)(OH)
S100A6 LQDAEIAR 915.5 (H)LQDAEIA(RC13N15)(OH)
PROL1 LNSPLSLPFVPGR 1396.8 (H)LNSPLSLPFVPG(RC13N15)(OH)
TF SASDLTWDNLK 1249.5 (H)SASDLTWDNL(KC13N15)(OH)
YWHAZ GIVDQSQQAYQEAFEISKK 2169.1 (H)GIVDQSQQAYQEAFEISK(KC13N15)(OH)
S100A9 LGHPDTLNQGEFK 1455.7 (H)LGHPDTLNQGEF(KC13N15)(OH)
CST4 IIPGGIYDADLNDEWVQR 2074.0 (H)IIPGGIYDADLNDEWVQ(RC13N15)(OH)
YWHAE EAAENSLVAYK 1194.6 (H)EAAENSLVAY(KC13N15)(OH)
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iTRAQ analyses were performed with 135 samples, as 
protein concentration of the remaining 5 samples was 
below the manufacturer’s suggested limit of 25  µg/sam-
ple. The corresponding limit for SWATH analysis was 
6 µg of protein and only one sample fell below this limit. 
We obtained corresponding data for 94 tear samples 
iTRAQ and SWATH analyses (Fig. 1).
We identified a total of 667 different proteins using 
iTRAQ in total of 13,220 peptides from 135 samples, cor-
responding to 310,452 identified spectra, and 477 pro-
teins had more than two peptides and were quantified. 
With SWATH we identified a total of 11,791 peptides 
from 60 samples, corresponding to 285,263 identified 
spectra in an assembly of 680 proteins using False dis-
covery rate of 1.0%. From this library, 456 proteins had 
more than two distinct peptides in all analyzed tear sam-
ples. The average amount of proteins identified in all time 
points of one patient by iTRAQ was 125, (range 59–258) 
and 49 proteins were quantified in all samples. Moreover, 
283 proteins were quantified with both analysis methods. 
iTRAQ is known to generate data with missing values, 
and we observed how, by allowing missing values, the 
number of quantified proteins increased (Fig.  2b). The 
SWATH protein library was more representative of the 
study as a whole. iTRAQ and SWATH libraries with pep-
tide information are presented in Additional file 1.
Data quality assessment
Each tear sample was run twice. In these replicate MS 
analyses, iTRAQ quantified an average of 125 and 
SWATH 456 proteins. In order to assess repeatability, we 
calculated and compared % RSD. At different % RSD cut-
off levels SWATH consistently showed higher number of 
proteins in relation to total number of quantified proteins 
(Fig. 3a, b).
To evaluate the effect of sample preparation and instru-
ment stability, we visualized protein expression variation 
of individual samples by boxplots (Fig. 3c, d). Variability 
between sample distributions was minor and medians 
were consistently close to zero, however, distribution var-
iation in iTRAQ was larger than in SWATH.
To correlate the fold change values between the two 
methods we compared the protein expression values 
obtained by iTRAQ to those of SWATH. There were alto-
gether 103 samples and 14 527relative changes in pro-
tein levels where this comparison was possible (Fig.  4). 
The relative changes were similar between two methods: 
70.6% of all proteins (and 76.1% of the 49 proteins seen 
in all samples) had less than onefold difference between 
corresponding iTRAQ and SWATH results (Fig.  4a, b). 
One iTRAQ sample was clearly deviating from the rest 
(Fig.  4a, b) and its removal from the data increased the 
correlation of iTRAQ and SWATH (Fig. 4c). This devia-
tion was also seen in the median and range in compari-
son to the other samples in iTRAQ box plot (Fig. 3c).
MS/MS validation using isotopically labeled peptides
Finally, we validated the SWATH and iTRAQ results 
using MicroLC-MS/MS analysis with AQUA pep-
tides. We selected 8 proteins with 1 peptide per pro-
tein and two different time-points (first and last) 
from 16 patients for the targeted quantification with 
isotopically labeled peptides. MS/MS method sample 
preparation together with instrument variation % RSD 
was < 15% for all peptides and instrument repeatabil-
ity alone < 5%. Linear range was confirmed in the range 
of 50 fold change and all peptides showed linearity of 
 r2 > 0.99. We calculated the protein expression fold 
change between first and last sample collection time 
points and compared it to SWATH-MS and iTRAQ 
Fig. 2 Protein quantification summary. a Number of analyzed proteins with iTRAQ and SWATH methods. b The effects of allowing missing values 
on the number of quantified proteins using iTRAQ (cumulative)
Page 7 of 11Jylhä et al. Clin Proteom  (2018) 15:24 
results respectively. MS/MS fold change comparison 
was possible with 114 values in SWATH analysis and 
110 values with iTRAQ. This comparison showed sim-
ilar results between the two methods with good corre-
lation to MS/MS. Median difference to MS/MS values 
were 0.33 [0.60 ± 0.79 (Mean ± SD)] using iTRAQ 
and 0.45 [0.62 ± 0.74 (Mean ± SD)] with SWATH-MS. 
Illustration of all 8 proteins results are represented in 
Additional file 2.
Clinical correlation of LYZ and S100A6 expression changes 
in two methods
In order to verify biological validity of the results we 
selected two known tear fluid biomarkers for longitudinal 
analysis. Lysozyme (LYZ) and S100A6 protein expres-
sions have been linked to dry eye disease and glaucoma 
drug adverse effects; LYZ expression decreases while 
S100A6 increases in response to these conditions [6, 7, 
20]. Both proteins were quantified in all samples using 
both analysis methods. In addition, our results demon-
strate good correlation between SWATH and iTRAQ 
(Fig. 5a). Based on protein expression levels of LYZ and 
S100A6 we were able to demonstrate that both patients 
are showing improvement on the ocular surface and that 
patient A reacts faster to the drug switch than patient B. 
Figure 5b result highlights the patient specific response, 
as we can see that in most cases LYZ is increased while 
S100A6 expression has gone down. Furthermore, patients 
Fig. 3 Data quality assessment. a Total number of relatively quantified proteins and b proportion of total analyzed proteins in technical replicates 
with RSD < 10, < 20 and < 40% (Mean ± SD, n(iTRAQ) = 125, n(SWATH) = 456). Distribution of proteomic results of individual samples analyzed with c 
iTRAQ, # one sample deviated from the rest in iTRAQ and d SWATH, expressed as mean of technical replicates  (log2-scale)
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Fig. 4 Variation of the results in iTRAQ and SWATH. Y-and x-axes represent the expression value  (log2-scaling) in each sample. a All results quantified 
in 94 samples by both methods, n = 14,473 relative fold change values (Spearman’s rank correlation coefficient  r2 = 0.345). b 49 proteins quantified 
in all iTRAQ samples correlated against SWATH results, n = 4606  (r2 = 0.414). c 49 proteins with one outlier sample removed  (r2 = 0.420). a and b 
highlighted parts represent the < 1 fold change difference between results
Fig. 5 Proteomic fold changes over time and comparison to targeted MS/MS analysis of specific peptides of two selected proteins (LYZ and 
S100A6). a Changes in LYZ and S100A6 protein expression levels over time relative to baseline expression, analyzed using iTRAQ, SWATH and MS/
MS in two representative patients. b Fold change results between baseline sample and 12 month sample in 16 patients. Presented proteins were 
selected based on their known biological function. iTRAQ and SWATH results are based on average of two replicate injections and AQUA peptides 
analysis on single technical replicate analysis
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appear to have very specific responses and the level of 
response varies between patients.
Discussion
This study compared two commonly used methods for 
relative quantitative proteomics (iTRAQ and SWATH) 
to demonstrate the particular value of SWATH analysis 
when confronted with the issues often found in clinical 
studies. In addition, we compared the results to isotopi-
cally labeled peptide standards (AQUA) using MicroLC-
MS/MS which showed that accuracy of SWATH and 
iTRAQ are at similar level and correlated well with abso-
lute concentration measured with isotopically labeled 
peptide standards. For studies conducted in controlled 
conditions with few time points, iTRAQ is useful in 
detecting relative changes in small samples such as tear 
fluid [6, 7, 28]. However, increasing numbers of patients 
and follow-up time points in clinical studies mean that 
label-free technologies such as SWATH provide a more 
consistent number of quantified results across all samples 
and thus is more suitable for the discovery of putative 
biomarkers.
Currently, the highest number of proteins identified 
from tear fluid samples is 1543. This result was obtained 
by using pooled samples and LC fractionation [6]. How-
ever, in clinical studies such as ours, study design requires 
individual sample preparation and analysis. Despite these 
restrictions, by combining iTRAQ and SWATH data we 
were able to identify 1055 and quantify 959 proteins (620 
with two peptides). Using iTRAQ only, we quantified a 
total of 667 (477 using two peptides) proteins without 
pooled samples and LC fractionation, which is almost 
double of what has been previously reported for tear fluid 
[20]. In addition, the average (125) and maximum (258) 
number of proteins quantified per patient was somewhat 
higher than reported previously [20, 29]. Proteome anal-
ysis using SWATH has been able to relatively quantify 
785 proteins from a 1 µl tear sample [9]. This technique 
allowed us to quantify 456 (680 including one peptide 
results) proteins in all of the tear fluid samples studied. Of 
these 477 (iTRAQ) and 456 proteins (SWATH), 283 were 
shared, leaving 173 proteins quantified only by iTRAQ 
and 173 only by SWATH. Similar difference between 
iTRAQ and SWATH data has been demonstrated previ-
ously in other types of samples [30, 31].
In our study the maximal number of proteins quantified 
with iTRAQ in all samples of one patient was 258. How-
ever, only 49 identical proteins were quantified in all sam-
ples of the 26 patients. This feature of iTRAQ has been 
characterized previously also by [20, 29]. The incomplete 
data in this type of study is generated based on stochastic 
selection of peptides [11, 31]. Various normalization and 
missing value imputation methods can correct variation 
and incomplete data to a certain extent [32, 33]. However, 
imputation methods in general have not gained much 
popularity because their validation is challenging [34]. 
Therefore, we chose not to use imputation algorithms to 
complete the data in this study.
When correlating the data obtained by using iTRAQ 
and SWATH we found that they were in a fairly good 
agreement. 70.6% of the 283 proteins quantified by both 
methods showed less than onefold change difference to 
each other and had a correlation coefficient of  r2 = 0.414. 
Several comparisons of iTRAQ and SWATH have been 
reported [30, 31, 35], but their results cannot be directly 
compared with ours due to the differences in study 
design and instrumentation. Our correlation coefficient 
was between previous study results [31, 35], showing cor-
relation of  r2 = 0.726 and  r2 = 0.312. Data variation seen 
in boxplots is probably due to sample processing and 
instrument variation in the SWATH analysis and labeling 
and instrument variation in iTRAQ analyses.
The differences in fold change values between iTRAQ 
and SWATH suggest that there is variation in the accu-
racy of the results. Overall, SWATH analysis yielded 
a wider range of fold change values than iTRAQ. Fold 
change underestimation in iTRAQ has been demon-
strated previously [31, 36, 37] and is due to the mixed 
MS/MS in complex samples where two precursor ions 
are selected to the same window for MS/MS. As a result, 
the average of two reporter ion intensities, instead of one, 
determines a single peptide fold change.
MRM (multiple reaction monitoring) using AQUA 
peptides is considered to be the gold standard and only 
method for absolute quantification of proteins using 
mass spectrometry [28]. Results showed that iTRAQ 
and SWATH median and mean values were close to 
each other but standard deviation was higher in iTRAQ. 
When focusing on single protein results, some differ-
ences between the methods were observed but it was not 
possible to identify a common nominator for the differ-
ences. Based on AQUA peptide results we can conclude 
that using these peptides, both methods are equally accu-
rate and are able to produce reliable relative quantifica-
tion data, although SWATH can gain higher number of 
quantified results per sample with same reliability. Fur-
ther validation of the results using western blotting or 
ELISA assays were not possible due to the low sample 
amounts.
As a clinical example, we selected two known mark-
ers of ocular surface pathologies [6, 19] proteins (LYZ 
and S100A6) for closer examination and compared the 
protein expression change over time using iTRAQ and 
SWATH. After the drug switch, we found an increase 
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in LYZ expression together with a decrease in S100A6 
expression as expected if drug switch is beneficial for 
the patient. SWATH and iTRAQ both revealed similar 
changes and the results correlated well to MS/MS data. 
However, as also noted previously, iTRAQ often underes-
timated fold changes [31, 36].
Conclusions
Label-free techniques are becoming accepted as suit-
able tools for clinical proteomic analyses, and it has 
been suggested that future workflow should use DDA 
methods only in the preliminary hypothesis stage [38, 
39]. Our data supports this view by demonstrating ben-
efits of SWATH in a study having typical clinical study 
design. Although SWATH has several advantages over 
iTRAQ, there are still some remaining issues. SWATH 
analysis is time consuming and will take at least twice 
as much instrument time as iTRAQ analysis. SWATH 
requires a spectrum library to be created before analyz-
ing any specific type of samples, which consumes instru-
ment time and may require additional samples. Despite 
the additional work at the initial stages, once the library 
is created, it can be used afterwards for similar sam-
ples. Overall the complexity of data is far greater using 
SWATH since it is not limited to specific study design, 
which allows basically unlimited number of hypotheses 
to be tested against the data. This highlights the impor-
tance of bioinformatics as comparisons between time 
points, patients and patient data leads to enormous data 
amounts and can easily lead to false positives. On the 
other side wider range of comparisons means that one 
clinical study can provide much more information. In 
addition to higher data completeness and smaller % RSD 
variation, SWATH is showing reliable expression level 
changes between time points. Overall, for larger and 
complex clinical studies our research results support the 
use of label free methods.
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